The earnings call highlighted significant strategic moves, including substantial debt reduction and leadership changes, which position the company for future growth. However, challenges remain, particularly in subscriber retention and revenue generation, exacerbated by the transition away from compounded medications and past bankruptcy proceedings.

Company Guidance

During the WeightWatchers Second Quarter 2025 Earnings Conference Call, it was highlighted that the company has made significant strides in its strategic reorganization, reducing its debt by over 70% to $465 million, which is expected to free up approximately $50 million of cash annually from lower interest expenses. The company also reported a 12% year-over-year increase in monthly subscription revenues per average subscriber (ARPU) and a 56% year-over-year growth in Clinical subscribers. However, total end-of-period subscribers declined by 17% year-over-year, ending at 3.2 million, partly due to challenges in behavioral member acquisition and the transition of Clinical members from compounded semaglutide to FDA-approved medications. The company achieved a 34% adjusted EBITDA margin and reported revenues of $189 million, down 6% from the previous year. Moving forward, WeightWatchers expects total combined revenues of $685 million to $700 million and adjusted EBITDA of $140 million to $150 million for fiscal 2025. The company is focused on restoring profitable growth through strategic investments and a clearer strategic direction.

Debt Reduction and NASDAQ Relisting

WeightWatchers reduced its debt by more than 70%, freeing up approximately $50 million of cash annually from lower interest expense, and is now relisted on NASDAQ under the ticker WW.

Growth in Clinical Subscribers and ARPU

Monthly subscription revenues per average subscriber (ARPU) increased 12% year-over-year in the second quarter, marking the third consecutive quarter of ARPU expansion. Clinical subscribers grew year-over-year by 56%.

New Leadership Appointments

Notable leadership additions include Julie Rice as Chief Experience Officer and Dr. Kim Boyd as Chief Medical Officer, enhancing the company's focus on experience and clinical offerings.

Strong Adjusted EBITDA Margin

Adjusted EBITDA margin was 34% in the predecessor period, up more than 900 basis points year-over-year, driven by disciplined cost management and lower marketing spend.

WW International, Inc. (WW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

WW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.15 / -	-0.579	―	―	―
Jul 31, 2025	2025 (Q2)	-0.03 / 9.70	0.293	3210.58% (+9.41)	―	―
May 06, 2025	2025 (Q1)	- / -2.11	-4.392	51.96% (+2.28)	―	―
Feb 27, 2025	2024 (Q4)	- / 0.31	-1.114	127.83% (+1.42)	―	―
Nov 06, 2024	2024 (Q3)	- / -0.58	0.542	-206.83% (-1.12)	―	―
Aug 01, 2024	2024 (Q2)	- / 0.29	0.647	-54.71% (-0.35)	―	―
May 02, 2024	2024 (Q1)	- / -4.39	-1.681	-161.27% (-2.71)	―	―
Feb 28, 2024	2023 (Q4)	- / -1.11	-0.461	-141.65% (-0.65)	―	―
Nov 02, 2023	2023 (Q3)	- / 0.54	-2.927	118.52% (+3.47)	―	―
Aug 03, 2023	2023 (Q2)	- / 0.65	-0.066	1080.30% (+0.71)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

WW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$42.19	$42.31	+0.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.